Skip to content
Search

Latest Stories

Tim Wentforth named as Boots parent WBA’s new CEO

Walgreens Boots Alliance, Boots UK’s parent company, has appointed Tim Wentforth as its new CEO, effective on 23 October.

He joined WBA at a pivotal time when the company plans to downsize the business while driving execution and creating greater value for employees, patients, customers and shareholders.


Wentforth replaced Rosalind Brewer, who stepped down on 1 September, after two years at the helm.

He joined from Evernorth, Cigna’s health services organisation based in Connecticut, where he served as its founding CEO.

Prior to Cigna, he also held top roles in companies including specialty pharmacy company Accredo and pharmacy benefit manager Express Scripts.

“He is an accomplished and respected leader with profound expertise in the payer and pharmacy space as well as supply chain, IT and Human Resources,” said Stefano Pessina, Executive Chairman, WBA.

“We are confident he is the right person to lead WBA’s next phase of growth into a customer-centric healthcare company.”

WBA shelved its plan to sell Boots in June 2022, citing difficulties for potential buyers in raising necessary funds due to financial market instability.

At present, there is widespread speculation about WBA's second attempt to divest its UK assets as part of its ongoing efforts to tight-size the company.

WBA’s goal is to be the independent partner of choice, not just in pharmacy but also in healthcare services where it can improve healthcare, lower costs, and help patients, the statement added.

In July, Boots announced that it is moving forward with its plan to close 300 stores in the UK, despite significant sales growth in the quarterly results.

The company achieved robust quarterly results, with retail sales climbing by 13.4 percent and a ninth consecutive quarter of market share growth.

“WBA has a differentiated model with the power to build on the company’s pharmacy strength and trusted brand to evolve healthcare delivery,” Wentforth said.

“I believe in WBA’s vision to be the leading partner in reimagining local healthcare and wellbeing for all.”

“I’ve spent my career working to improve the health of the patients we’ve served,” he added.

"I believe WBA is well positioned to deliver more personalised, coordinated care and achieve better outcomes at a lower cost.”

“I fully recognise the challenges that health plans, healthcare providers, pharmacies and retailers are confronting today and am confident that WBA and its customer and patient-focused teams can seize the opportunities of a dynamic marketplace and be the partner of choice,” he further said.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less